ClinicalTrials.gg
RecruitingNCT07679061Updated Jul 1, 2026

First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

An observational study in Unresectable Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb. Recruiting at 2 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Bristol-Myers Squibb · Observational

How we know · 5 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb — 3 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Hepatocellular · Bristol-Myers Squibb.

Started
2026
with 1 other
Observational
2 of 21
1 open now
Registered
21st of 21
by date

Among the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 21st registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

3 of the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study looks at how a combination of two medicines, nivolumab and ipilimumab, is used to treat people with advanced liver cancer that cannot be removed by surgery. The study will follow adults receiving this treatment in routine medical care in Japan to understand how safe it is, how well it works, and how it is used in standard clinical practice.

03

Conditions studied

  • Unresectable Hepatocellular Carcinoma

Keywords

  • Hepatocellular carcinoma; HCC; nivolumab; ipilimumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults in Japan with Child-Pugh class A unresectable hepatocellular carcinoma initiating first-line nivolumab plus ipilimumab in routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged ≥ 18 years at the time of consent
  • Participants with unresectable hepatocellular carcinoma (uHCC), defined as disease not eligible for curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies
  • class A (total score 5-6)
  • Participants who have not received prior systemic drug therapy for uHCC

    • Participants who more than 6 months after completion of postoperative therapy are eligible
    • Participants who received lenvatinib in combination with transarterial chemoembolization (TACE) are eligible if the treating physician determined they were eligible for TACE; participants are excluded if TACE eligibility at the time of lenvatinib initiation is unclear
  • Participants scheduled to initiate nivolumab plus ipilimumab combination therapy between March 1, 2026 and February 28, 2027

    • Nivolumab plus ipilimumab combination therapy is defined as nivolumab 80 mg and ipilimumab 3 mg/kg administered intravenously every 3 weeks for 4 cycles, followed by nivolumab monotherapy at 240 mg every 2 weeks or 480 mg every 4 weeks
  • Participants who provide written prior to initiation of nivolumab plus ipilimumab therapy

Exclusion criteria

Exclusion Criteria:

  • Known fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or mixed cholangiocarcinoma
  • Prior liver transplant
  • performance status ≥ 3
  • Uncontrolled comorbidities despite treatment
  • Other advanced cancers requiring systemic therapy
  • Prior immuno-oncology treatment
  • Participation in interventional clinical trials at enrollment
  • Deemed unsuitable by investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Nivolumab plus ipilimumab cohort

    Participants with unresectable hepatocellular carcinoma receiving nivolumab plus ipilimumab as first-line systemic therapy in routine clinical practice in Japan.

    Combination Product: Nivolumab plus ipilimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with grade ≥3 immune-mediated liver injury (IMLI)

    Number of participants who experience grade 3-5 immune-mediated liver injury (IMLI), defined as treatment-related hepatic adverse events assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to 2 years

  2. Time to onset of immune-mediated liver injury (IMLI)

    Time from first dose of nivolumab plus ipilimumab to first occurrence of immune-mediated liver injury (any grade).

    Time frame: Up to 2 years

  3. Time to resolution of immune-mediated liver injury (IMLI)

    Time from onset of immune-mediated liver injury to resolution, defined as recovery, recovery with sequelae, or improvement per clinician assessment.

    Time frame: Up to 2 years

  4. Number of participants with immune-mediated liver injury (IMLI) who achieve resolution (recovered, recovering, or recovered with sequelae)

    Time frame: Up to 2 years

  5. Treatment prescribed to participants for immune-mediated liver injury (IMLI)

    Time frame: Up to 2 years

  6. Objective response rate (ORR)

    Number of participants with complete response (CR) or partial response (PR) as best overall response among participants with baseline target lesions, assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to 2 years

  7. Best overall response (BOR)

    Distribution of best overall response categorized as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE) among participants with baseline target lesions per RECIST v1.1.

    Time frame: Up to 2 years

  8. Disease control rate (DCR

    Number of participants with complete response (CR), partial response (PR), or stable disease (SD) as best overall response among participants with baseline target lesions per RECIST v1.1.

    Time frame: Up to 2 years

  9. Duration of nivolumab plus ipilimumab combination therapy

    Time from first dose of nivolumab plus ipilimumab to treatment discontinuation.

    Time frame: Up to 2 years

  10. Number of nivolumab plus ipilimumab treatment cycles per participant

    Total number of administered cycles of nivolumab plus ipilimumab given every 3 weeks, summarized per participant.

    Time frame: Up to 2 years

  11. Number of participants who discontinue treatment

    Number of participants who discontinue nivolumab plus ipilimumab.

    Time frame: Up to 2 years

  12. Reasons for treatment discontinuation

    Distribution of reasons, including disease progression, adverse events death, participant request, transfer, or other reasons as assessed by treating clinician.

    Time frame: Up to 2 years

Secondary outcomes

  1. Number of participants with immune-mediated adverse events (IMAEs)

    Number of participants experiencing IMAEs, defined as treatment-related adverse events with immune-mediated etiology, categorized by CTCAE v5.0 grade (1-5).

    Time frame: Up to 2 years

  2. Time to onset of immune-mediated adverse events (IMAEs)

    Time from treatment initiation to onset of immune-mediated adverse events.

    Time frame: Up to 2 years

  3. Time to resolution of immune-mediated adverse events (IMAEs)

    Time from onset of immune-mediated adverse events to resolution.

    Time frame: Up to 2 years

  4. Number of participants with immune-mediated adverse events (IMAEs) who achieve resolution (recovered, recovering, or recovered with sequelae)

    Time frame: Up to 2 years

  5. Treatment prescribed to participants for immune-mediated adverse events (IMAEs)

    Time frame: Up to 2 years

  6. Number of participants with of immune-mediated adverse events (IMAEs) leading to treatment discontinuation

    Time frame: Up to 2 years

  7. Number of participants with treatment-related adverse events (TRAEs)

    Number of participants experiencing treatment-related adverse events categorized by preferred term and CTCAE v5.0 grade.

    Time frame: Up to 2 years

  8. Time to onset of treatment-related adverse events (TRAEs)

    Time from treatment initiation to onset of immune-mediated adverse events.

    Time frame: Up to 2 years

  9. Time to resolution of treatment-related adverse events (TRAEs)

    Time from onset of immune-mediated adverse events to resolution.

    Time frame: Up to 2 years

  10. Number of participants with treatment-related adverse events (TRAEs) who achieve resolution (recovered, recovering, or recovered with sequelae)

    Time frame: Up to 2 years

  11. Number of participants with treatment-related adverse events (TRAEs) leading to treatment discontinuation

    Time frame: Up to 2 years

  12. Duration of response (DOR)

    Time from first documented complete response (CR) or partial response (PR) to disease progression per RECIST v1.1 or death from any cause, whichever occurs first

    Time frame: Up to 2 years

  13. Overall survival (OS

    Time from first dose of nivolumab plus ipilimumab to death from any cause.

    Time frame: Up to 2 years

  14. Progression-free survival (PFS)

    Time from first dose of nivolumab plus ipilimumab to first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: Up to 2 years

  15. Second progression-free survival (PFS2)

    Time from first dose of nivolumab plus ipilimumab to progression after second-line therapy or death from any cause, whichever occurs first.

    Time frame: Up to 2 years

  16. Depth of response (DpR)

    Maximum percentage reduction from baseline in the sum of diameters of target lesions among participants with measurable disease.

    Time frame: Up to 2 years

  17. Change from baseline in Child-Pugh score

    Change from baseline in Child-Pugh score (range 5-15), including classification into Class A, B, or C.

    Time frame: Up to 2 years

  18. Change from baseline in albumin-bilirubin (ALBI) and modified ALBI (mALBI) grades based on laboratory values.

    Time frame: Up to 2 years

  19. Number of participants receiving subsequent therapy

    Number of participants who receive any subsequent anticancer therapy after discontinuation of nivolumab plus ipilimumab

    Time frame: Up to 2 years

  20. Type of subsequent therapy received

    Distribution of subsequent therapies received after discontinuation of nivolumab plus ipilimumab, including transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), radiofrequency ablation (RFA), surgery, radiation therapy, and systemic therapies.

    Time frame: Up to 2 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2028, 23 months after the start.

Of 49 industry-sponsored observational studies under Carcinoma, Hepatocellular, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 23 months is below that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 1, 2026
StartActual
Mar 5, 2026
Primary completionEst.
Feb 29, 2028
CompletionEst.
Feb 29, 2028
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07679061
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Mar 5, 2026
Primary completion
Feb 29, 2028 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Jul 1, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion